Oxford BioDynamics, a biotech company focused on the epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has appointed new chief financial officer who is expected to join the company by the mid of September 2017.
Paul Stockdale, the new CFO will be appointed to the Board of Directors, as he succeeds Katie Long who is returning to her role within Tessera Investment Management Limited (Tessera), having established and led OBD’s finance function over the previous nine months and during Oxfor BioDynamics’ IPO. Long will step down from the Board on Friday (June 30, 2017) and will support OBD on an interim basis in the transitional period.
Stockdale joins the Company from e-Therapeutics, where he has held the position of Financial Controller since January 2012.
Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said: “We are delighted to welcome Paul Stockdale to the Company. Paul’s extensive financial management experience, including his recent experience in another public company focused on drug discovery, will be important as OBD strides towards becoming the industry standard for epigenetic biomarker discovery.
The Board would like to take this opportunity to thank Katie for her invaluable contribution during this pivotal time for OBD. We wish her well on her return to Tessera.”